Abstract:Cancer is a devastating disease and a large socio-economic burden. Novel therapeutic solutions are on the rise, although a cure remains elusive. Application of microorganisms represents an ancient therapeutic strategy, lately revoked and refined via simultaneous attenuation and amelioration of pathogenic properties. Salmonella Typhimurium has prevailed in preclinical development. Yet, using virulent strains for systemic treatment might cause severe side effects. In the present study, we highlight a modified strain based on Salmonella Typhimurium UK-1 expressing hexa-acylated Lipid A. We corroborate improved anti-tumor properties of this strain and investigate to which extent an intra-tumoral (i.t.) route of infection could help improve safety and retain advantages of systemic intravenous (i.v.) application. Our results show that i.t. infection exhibits therapeutic efficacy against CT26 and F1.A11 tumors similar to a systemic route of inoculation. Moreover, i.t. application allows extensive dose titration without compromising tumor colonization. Adverse colonization of healthy organs was generally reduced via i.t. infection and accompanied by less body weight loss of the murine host. Despite local application, adjuvanticity remained, and a CT26-specific CD8+ T cell response was effectively stimulated. Most interestingly, also secondary tumors could be targeted with this strategy, thereby extending the unique tumor targeting ability of Salmonella. The i.t. route of inoculation may reap the benefits of systemic infection and aid in safety assurance while directing potency of an oncolytic vector to where it is most needed, namely the primary tumor.

Salmonella-based therapeutic strategies: improving tumor microenvironment and bringing new hope for cancer immunotherapy

Targeted cancer immunotherapy with genetically engineered oncolytic Salmonella typhimurium.

Advances in Salmonella Typhimurium-based Drug Delivery System for Cancer Therapy.

Genetically Engineered Salmonella Typhimurium: Recent Advances in Cancer Therapy.

[Advances in Tumor-Therapy Using Genetically Modified Salmonella].

New technologies in developing recombinant-attenuated bacteria for cancer therapy

New Technologies in Developing Recombinant‐attenuated Bacteria for Cancer Therapy

Local application of bacteria improves safety of Salmonella -mediated tumor therapy and retains advantages of systemic infection

Harnessing Bacterial Agents to Modulate the Tumor Microenvironment and Enhance Cancer Immunotherapy

Repolarizing neutrophils via MnO2 nanoparticle-activated STING pathway enhances Salmonella-mediated tumor immunotherapy

Targeted Cancer Therapy Using Engineered Salmonella typhimurium.

Cytokines and soluble mediators as architects of tumor microenvironment reprogramming in cancer therapy

S100a8/a9 regulated by LPS/TLR4 axis plays an important role in Salmonella-based tumor therapy and host defense

Tumor-targeting bacteria as immune stimulants – the future of cancer immunotherapy?

Current Status and Future Directions of Bacteria-Based Immunotherapy

Bacteria-based immunotherapy for cancer: a systematic review of preclinical studies

Salmonella Breaks Tumor Immune Tolerance by Downregulating Tumor Programmed Death-Ligand 1 Expression

Path to bacteriotherapy: From bacterial engineering to therapeutic perspectives

Salmonella immunotherapy engineered with highly efficient tumor antigen coating establishes antigen-specific CD8+ T cell immunity and increases in antitumor efficacy with type I interferon combination therapy

Bacteria-mediated Cancer Therapy: A Versatile Bio-Sapper with Translational Potential

Programmable Bacteria with Dynamic Virulence Modulation System for Precision Antitumor Immunity